AEON Biopharma (AEON) 10% holder now owns 6.5M shares

Rhea-AI Filing Summary

AEON Biopharma, Inc. (AEON) reported that ten percent owner Timothy P. Lynch purchased 1,150,000 shares of Class A Common Stock on August 19, 2026. The weighted average purchase price was $0.2117 per share, with individual trades ranging from $0.1975 to $0.2164. Following this open-market purchase, Lynch directly owns 6,500,000 shares of AEON Class A Common Stock.

Insider Trade Summary

Net Buyer: 1,150,000 shares

Net Buy 1 txn

Insider LYNCH TIMOTHY P

Role 10% Owner

Bought 1,150,000 shs ($243K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock F1	1,150,000	$0.2117	$243K

Holdings After Transaction: Class A Common Stock — 6,500,000 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1975 to $0.2164 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Key Figures

Shares purchased: 1,150,000 shares of Class A Common Stock Weighted average purchase price: $0.2117 per share Purchase price range: $0.1975 to $0.2164 per share +2 more

5 metrics

Shares purchased 1,150,000 shares of Class A Common Stock Non-derivative purchase on August 19, 2026

Weighted average purchase price $0.2117 per share Open-market or private transactions on August 19, 2026

Purchase price range $0.1975 to $0.2164 per share Range of prices for multiple trades included in the reported purchase

Shares owned after transaction 6,500,000 shares Direct ownership following the August 19, 2026 purchase

Net buy shares 1,150,000 shares Net effect of reported Form 4 transactions

Key Terms

weighted average price, ten percent owner, Class A Common Stock, non-derivative

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

ten percent owner regulatory

"Reporting person is indicated as a ten percent owner of the issuer."

Class A Common Stock financial

"Security title is reported as Class A Common Stock."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

non-derivative financial

"Transaction type is identified as non-derivative."

FAQ

What insider transaction did AEON (AEON) disclose in this Form 4?

AEON disclosed that ten percent owner Timothy P. Lynch purchased 1,150,000 shares of its Class A Common Stock on August 19, 2026 in an open-market or private transaction at a weighted average price of $0.2117 per share.

At what prices did Timothy P. Lynch buy AEON (AEON) shares?

The filing states a weighted average price of $0.2117 per share. The individual transactions occurred at prices ranging from $0.1975 to $0.2164 per share, according to the footnote describing the trade range.

How many AEON (AEON) shares does Timothy P. Lynch own after this transaction?

After the reported purchase, Timothy P. Lynch directly owns 6,500,000 shares of AEON Biopharma, Inc. Class A Common Stock, as stated in the post-transaction holdings column of the Form 4.

Was the AEON (AEON) insider trade made under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not checked (aff_10b5_one is false), and the footnote does not mention a trading plan, so the filing does not describe this purchase as made under a Rule 10b5-1 plan.

What type of security did the AEON (AEON) insider purchase?

Timothy P. Lynch purchased Class A Common Stock of AEON Biopharma, Inc., as specified in the non-derivative securities section of the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 07:41 PM Accepted by SEC EDGAR 08/21/2026 - 07:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LYNCH TIMOTHY P

(Last) (First) (Middle)

70 SW CENTURY DR.

STE. 100

(Street)

BEND OREGON 97702

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AEON Biopharma, Inc. [ AEON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/19/2026		P		1,150,000	A	$0.2117(1)	6,500,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1975 to $0.2164 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

	/s/ Timothy P. Lynch	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)